| |
|
Randomization Group |
|
| |
Overall |
‘Abacavir group’ |
‘Tenofovir Group’ |
P-value* |
| Total Sample, number |
27 |
13 |
14 |
|
| Age, median (IQR) years |
46 [41, 53] |
47 [43, 53] |
42.5 [32, 52] |
0.30 |
| Male Gender, # (%) |
26 (96.3%) |
12 (92.3%) |
14 (100.0%) |
0.30 |
| Race/Ethnicity, # (%) |
|
|
|
0.36 |
| White |
22 (81.5%) |
10 (76.9%) |
12 (85.7%) |
|
| African American |
4 (14.8%) |
3 (23.1%) |
1 (7.1%) |
|
| Hispanic |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
|
| Other |
1 (3.7%) |
0 (0.0%) |
1 (7.1%) |
|
| IDU, # (%) |
|
|
|
0.13 |
| Prior |
2 (7) |
2 (15) |
0 (0) |
|
| Never |
25 (93) |
11 (85) |
14 (100) |
|
| Hep B or C positive, # (%) |
3 (11) |
2 (15) |
1 (7) |
0.30 |
| Current Smoker, # (%) |
6 (22) |
3 (23) |
3 (21) |
0.92 |
| Blood pressure lowering therapy, # (%) |
4 (16) |
4 (31) |
0 (0) |
0.10 |
| Lipid lowering therapy, # (%) |
6 (23) |
3 (23) |
3 (23) |
>0.99 |
| Tot. Chol., median (IQR) mg/dL |
201 (178, 238) |
205 (185, 214) |
189 (178, 243) |
0.75 |
| LDL-C, median (IQR) mg/dL |
107 (91, 127) |
100 (93, 127) |
108 (91, 126) |
0.81 |
| HDL-C, median (IQR) mg/dL |
43 (36, 55) |
42 (36, 48) |
49 (36, 59) |
0.27 |
| Framingham Risk Score, median (IQR) % coronary event over 10yrs |
6.0 (3.6, 10.4) |
8.5 (5.6, 12.8) |
4.7 (2.3, 7.9) |
0.052 |
| Biomarkers |
|
|
|
|
| hsCRP, median (IQR) μg/mL |
2.1 (0.9, 3.2) |
2.1 (1.2, 2.8) |
2.3 (0.9, 3.2) |
0.78 |
| IL-6, median (IQR) pg/mL |
1.7 (1.2, 2.3) |
1.7 (1.5, 2.2) |
2.1 (1.0, 2.3) |
0.78 |
| D-dimer, median (IQR) μg/mL |
0.2 (0.1, 0.2) |
0.2 (0.1, 0.5) |
0.1 (0.1, 0.2) |
0.02 |
| ADMA, median (IQR) μmol/L |
0.6 (0.5, 0.7) |
0.6 (0.5, 0.7) |
0.6 (0.5, 0.8) |
0.47 |
| sICAM-1, median (IQR) ng/mL |
228 (184, 274) |
228 (172, 274) |
227 (190, 253) |
0.98 |
| vWF, median (IQR) % |
122 (108, 153) |
133 (110, 183) |
120 (108, 133) |
0.34 |
| sTM, median (IQR) pg/mL |
4944 (4145, 5945) |
5382 (4096, 5945) |
4882 (4567, 5561) |
0.94 |
* P-values are from comparisons between groups, using Wilcoxon or Chi-square as appropriate. |
